Citigroup’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.02M | Hold |
15,000
| – | – | ﹤0.01% | 3102 |
|
|
2025
Q4 | $1.14M | Buy |
+15,000
| New | +$1.09M | ﹤0.01% | 3055 |
|
|
2025
Q3 | – | Sell |
-30,000
| Closed | -$1.47M | – | 6270 |
|
|
2025
Q2 | $1.47M | Hold |
30,000
| – | – | ﹤0.01% | 2918 |
|
|
2025
Q1 | $1.53M | Buy |
+30,000
| New | +$1.5M | ﹤0.01% | 2940 |
|
|
2024
Q4 | – | Sell |
-13,500
| Closed | -$501K | – | 5922 |
|
|
2024
Q3 | $501K | Buy |
+13,500
| New | +$452K | ﹤0.01% | 3725 |
|
|
2024
Q2 | – | Sell |
-24,800
| Closed | -$721K | – | 5737 |
|
|
2024
Q1 | $721K | Buy |
+24,800
| New | +$695K | ﹤0.01% | 3286 |
|
|
2023
Q3 | – | Sell |
-60,000
| Closed | -$2.44M | – | 5767 |
|
|
2023
Q2 | $2.44M | Buy |
60,000
+30,200
| +101% | +$1.48M | ﹤0.01% | 2023 |
|
|
2023
Q1 | $1.44M | Sell |
29,800
-21,400
| -42% | -$978K | ﹤0.01% | 2251 |
|
|
2022
Q4 | $1.95M | Buy |
51,200
+26,200
| +105% | +$1.09M | ﹤0.01% | 2060 |
|
|
2022
Q3 | $1.25M | Sell |
25,000
-5,000
| -17% | -$245K | ﹤0.01% | 2537 |
|
|
2022
Q2 | $1.2M | Buy |
+30,000
| New | +$1.05M | ﹤0.01% | 2507 |
|
|
2020
Q4 | – | Sell |
-33,900
| Closed | -$1.58M | – | 7574 |
|
|
2020
Q3 | $1.58M | Sell |
33,900
-2,500
| -7% | -$123K | ﹤0.01% | 2874 |
|
|
2020
Q2 | $1.85M | Hold |
36,400
| – | – | ﹤0.01% | 2900 |
|
|
2020
Q1 | $1.62M | Sell |
36,400
-14,700
| -29% | -$740K | ﹤0.01% | 2693 |
|
|
2019
Q4 | $2.45M | Buy |
51,100
+20,500
| +67% | +$871K | ﹤0.01% | 2772 |
|
|
2019
Q3 | $1.03M | Buy |
30,600
+24,100
| +371% | +$1.05M | ﹤0.01% | 3609 |
|
|
2019
Q2 | $293K | Buy |
6,500
+3,600
| +124% | +$142K | ﹤0.01% | 4942 |
|
|
2019
Q1 | $109K | Sell |
2,900
-100
| -3% | -$3.36K | ﹤0.01% | 5662 |
|
|
2018
Q4 | $103K | Sell |
3,000
-100
| -3% | -$3.6K | ﹤0.01% | 5627 |
|
|
2018
Q3 | $146K | Sell |
3,100
-900
| -23% | -$37.2K | ﹤0.01% | 5542 |
|
|
2018
Q2 | $135K | Sell |
4,000
-1,600
| -29% | -$49.9K | ﹤0.01% | 5433 |
|
|
2018
Q1 | $152K | Buy |
5,600
+2,500
| +81% | +$63.3K | ﹤0.01% | 5230 |
|
|
2017
Q4 | $52K | Sell |
3,100
-11,300
| -78% | -$191K | ﹤0.01% | 6157 |
|
|
2017
Q3 | $288K | Buy |
14,400
+14,200
| +7,100% | +$278K | ﹤0.01% | 4666 |
|
|
2017
Q2 | $4K | Hold |
200
| – | – | ﹤0.01% | 6819 |
|
|
2017
Q1 | $2K | Sell |
200
-34,400
| -99% | -$416K | ﹤0.01% | 7007 |
|
|
2016
Q4 | $377K | Buy |
34,600
+28,100
| +432% | +$295K | ﹤0.01% | 4674 |
|
|
2016
Q3 | $91K | Buy |
6,500
+6,100
| +1,525% | +$49.6K | ﹤0.01% | 5266 |
|
|
2016
Q2 | $3K | Buy |
+400
| New | +$2.93K | ﹤0.01% | 6874 |
|
|
2016
Q1 | – | Sell |
-2,500
| Closed | -$81K | – | 7698 |
|
|
2015
Q4 | $81K | Hold |
2,500
| – | – | ﹤0.01% | 5539 |
|
|
2015
Q3 | $67K | Hold |
2,500
| – | – | ﹤0.01% | 5237 |
|
|
2015
Q2 | $120K | Buy |
+2,500
| New | +$146K | ﹤0.01% | 4858 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Citigroup's PTCT Position: Q1 2026 in Review
Citigroup reduced its PTC Therapeutics (PTCT) stake by 32% in Q1 2026, selling an estimated $745K and leaving 22,146 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2850.
Citigroup first reported a position in PTCT in Q3 2013 and has held it in 51 quarters since. The position peaked at $15.6M in Q1 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Citigroup held 22,146 shares of PTC Therapeutics worth $1.51M as of Q1 2026.
- Citigroup sold 10,515 PTC Therapeutics shares in Q1 2026, an estimated $745K.
- PTC Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2850 holding.
- Citigroup first reported a position in PTC Therapeutics in Q3 2013 and has held it in 51 quarters since.
- Citigroup's PTC Therapeutics position peaked at $15.6M in Q1 2025.
- 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.